NO20044865L - Karbonmonoksid som biomarkor og terapeutisk middel - Google Patents

Karbonmonoksid som biomarkor og terapeutisk middel

Info

Publication number
NO20044865L
NO20044865L NO20044865A NO20044865A NO20044865L NO 20044865 L NO20044865 L NO 20044865L NO 20044865 A NO20044865 A NO 20044865A NO 20044865 A NO20044865 A NO 20044865A NO 20044865 L NO20044865 L NO 20044865L
Authority
NO
Norway
Prior art keywords
disease
lung
cancer
biomarker
therapeutic agent
Prior art date
Application number
NO20044865A
Other languages
English (en)
Norwegian (no)
Inventor
Leo E Otterbein
Augustine M K Choi
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of NO20044865L publication Critical patent/NO20044865L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20044865A 2002-05-09 2004-11-09 Karbonmonoksid som biomarkor og terapeutisk middel NO20044865L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/014836 WO2003094932A1 (en) 2002-05-09 2002-05-09 Carbon monoxide as a biomarker and therapeutic agent

Publications (1)

Publication Number Publication Date
NO20044865L true NO20044865L (no) 2004-12-07

Family

ID=29418043

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044865A NO20044865L (no) 2002-05-09 2004-11-09 Karbonmonoksid som biomarkor og terapeutisk middel

Country Status (13)

Country Link
EP (1) EP1501523A4 (sr)
JP (1) JP2005532314A (sr)
KR (1) KR20040106515A (sr)
CN (1) CN1638781A (sr)
AU (1) AU2002308676B2 (sr)
BR (1) BR0215717A (sr)
CA (1) CA2484770A1 (sr)
EA (1) EA200401478A1 (sr)
MX (1) MXPA04011113A (sr)
NO (1) NO20044865L (sr)
RS (1) RS96904A (sr)
UA (1) UA84402C2 (sr)
WO (1) WO2003094932A1 (sr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP2042181A1 (en) 2002-02-04 2009-04-01 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
CA2481786A1 (en) 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
EA200401365A1 (ru) 2002-04-15 2005-04-28 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Способы лечения илеуса
HRP20041071A2 (en) * 2002-05-17 2005-06-30 Yale University University of Pittsburgh of the Commonwealth Syste Methods of treating hepatitis
JP2005345242A (ja) * 2004-06-02 2005-12-15 Tohoku Univ 肺癌の化学療法治療効果の評価方法
WO2007073005A1 (ja) * 2005-12-22 2007-06-28 Keio University メチル基転移反応調節物質
EP2099439A2 (en) * 2006-12-06 2009-09-16 Alfama - Investigação E Desenvolvimento De Produto Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2010094122A (ja) 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
CN109925318A (zh) * 2011-01-14 2019-06-25 洛杉矶儿童医院 用于治疗包括镰状细胞疾病的疾病的一氧化碳溶液
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
US9365419B2 (en) 2011-03-24 2016-06-14 Technion Research & Development Foundation Ltd. Method of diagnosing, prognosing and monitoring alzheimer's disease
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
WO2014165732A1 (en) 2013-04-04 2014-10-09 The Regents Of The University Of California System and method for utilizing exhaled breath for monitoring inflammatory states
EP2868348A1 (en) * 2013-11-04 2015-05-06 Universität Zürich CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair
TW201618795A (zh) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
JP7161737B2 (ja) * 2017-01-30 2022-10-27 哲也 石川 悪性腫瘍の検査方法
JP7396598B2 (ja) * 2018-06-08 2023-12-12 住友精化株式会社 皮膚創傷用組成物
JP7396597B2 (ja) 2018-06-08 2023-12-12 住友精化株式会社 炎症性消化器官疾患用組成物
WO2020247825A1 (en) * 2019-06-06 2020-12-10 The General Hospital Corporation Carbon monoxide as a treatment for neurodegenerative disease
WO2022015986A1 (en) * 2020-07-16 2022-01-20 Cornell University Methods for treating metastatic cancer using low dose carbon monoxide
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
CN1191836C (zh) * 1996-08-27 2005-03-09 梅塞尔集团有限公司 氢气作为药物活性成分在制备药物产品中的用途
EP1381354A2 (en) * 2001-03-30 2004-01-21 Sangstat Medical Corporation Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders

Also Published As

Publication number Publication date
UA84402C2 (ru) 2008-10-27
MXPA04011113A (es) 2005-02-14
EA200401478A1 (ru) 2005-12-29
EP1501523A1 (en) 2005-02-02
KR20040106515A (ko) 2004-12-17
RS96904A (sr) 2007-02-05
CN1638781A (zh) 2005-07-13
AU2002308676A1 (en) 2003-11-11
AU2002308676B2 (en) 2009-06-11
BR0215717A (pt) 2005-02-22
EP1501523A4 (en) 2006-12-13
JP2005532314A (ja) 2005-10-27
CA2484770A1 (en) 2003-11-20
WO2003094932A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
NO20044865L (no) Karbonmonoksid som biomarkor og terapeutisk middel
NO20070994L (no) N-hydroksamid derivater og anvendelse derav
EP2301952A3 (en) Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
DE60237969D1 (de) Menschliche antikörper gegen timp-1
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
WO2005086915A3 (en) Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
Fitton et al. Impact of secondary pulmonary hypertension on lung transplant outcome
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
NO20054336L (no) Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer
Talwalkar et al. Outcome of isolated coronary artery bypass surgery in octogenarians
EA200200518A1 (ru) Способ и композиция для лечения заболеваний легких
IL180681A0 (en) Pyridine derivatives, their preparation and use
IS5793A (is) Útskiptir beta-díketónar og notkun þeirra
DK1828160T3 (da) Cykliske sulfonylaminoderivater og anvendelse deraf som MMP-hæmmere
YANG et al. The Impact of the Jagged1/Notch1 Signalling Pathway on Endothelial-mesenchymal Transition in Idiopathic Pulmonary Fibrosis
NO20074458L (no) N-hydroksamidderivater og anvendelse derav
San-Huang α-Macroglobulins: a modulator for growth factors
YU78800A (sh) Supstituisani beta-diketoni i njihova upotreba
Kim et al. Design, Synthesis, and Biological Evaluation of Novel Vinyl Selenone Derivatives as Potent Nrf2 Activators for Atopic Dermatitis
ATE328120T1 (de) Bakterienstämme delftia acidovorans mc1-r, ihre herstellung sowie ihre verwendung zur produktion der r-enantiomeren von 2-phenoxypropionsäure- derivaten
UA88785C2 (en) N-hydroxyamide derivatives and use thereof
Green et al. Water for Life: The Impact of the Privatization of Water Services on Child Mortality.
Mansfield et al. Pulmonary veno-occlusive disease in association with crest syndrome (limited scleroderma): clinical, radiologic, hemodynamic and pathologic characterization
NO20073633L (no) Sulfonylamino sykliske derivater og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application